Beam Cleared to Launch Trial of BEAM-101, Gene Editing Therapy

Beam Cleared to Launch Trial of BEAM-101, Gene Editing Therapy

312130

Beam Cleared to Launch Trial of BEAM-101, Gene Editing Therapy

The U.S. Food and Drug Administration (FDA) has cleared Beam Therapeutics to start clinical testing of BEAM-101, the company’s investigational gene editing cell therapy for sickle cell disease (SCD). “BEAM-101 has the potential to offer a one-time treatment for patients with sickle cell disease, and this clearance enables the important transition from a preclinical to a clinical-stage company, bringing us closer to our ultimate goal of helping patients,” John Evans, Beam’s CEO, said in a press…

You must be logged in to read/download the full post.